Cryo-Cell InternationalSTU:ZCY -2.52%58 Net Margin % is 0.62% as of Feb. 2026, which is 85% below its 10-year median of 4.23. GuruFocus rates STU:ZCY with a GF Score™ of 58/100 and a GF Value™ of €6.10 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 665 Healthcare Providers & Services companies, Cryo-Cell International ranks worse than 75.34% on this metric.
The historical rank and industry rank for Cryo-Cell International's Net Margin % or its related term are showing as below:
STU:ZCY'
s Net Margin % Range Over the Past 10 Years
Min: -30.38 Med: 4.23 Max: 11.64
Current: -8.52
STU:ZCY's Net Margin % is ranked worse than 75.34% of 665
companies
in the Healthcare Providers & Services industry
Industry Median: 2.89
vs STU:ZCY: -8.52
Cryo-Cell International (STU:ZCY) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Cryo-Cell International Net Margin % Related Terms
Cryo-Cell International Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ZCY vs CCM, CDIX, EHSI: Net Margin % Comparison
For the Medical Care Facilities subindustry, Cryo-Cell International's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International Net Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Net Margin % distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International (STU:ZCY) has a Net Margin % of 0.62% as of Feb. 2026. Net margin is the ratio of total net income to net sales. View historical data on Cryo-Cell International and its competitors. This is 85% below median its historical median of 4.23. According to the industry distribution chart, Cryo-Cell International ranks #501 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 75.3%.
Is Cryo-Cell International's Net Margin % too high?
Cryo-Cell International's current Net Margin % of 0.62% is 85% below median its 10-year median of 4.23. The Healthcare Providers & Services industry median Net Margin % is 2.89. Cryo-Cell International's value of 0.62% is 78.5% below this industry median. Based on the distribution chart, Cryo-Cell International ranks #501 out of 665 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Net Margin % compare to CCM and CDIX?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #501 out of 665 companies for Net Margin %. This places Cryo-Cell International in the lower half of its industry. The industry median Net Margin % is 2.89. Cryo-Cell International's value of 0.62% is 78.5% below this benchmark. While the company's 10-year median is 4.23 vs. the industry median of 2.89, Cryo-Cell International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Healthcare Providers & Services company?
The median Net Margin % among Healthcare Providers & Services companies is 2.89, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryo-Cell International's current Net Margin % of 0.62% is 78.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median Net Margin % is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current Net Margin % is 0.62%, which is 85% below median its own 10-year median of 4.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (STU:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €6.10, compared to a current price of €3.10 — trading 49.2% below its estimated fair value. The current Net Margin % is 0.62%, which is 85% below median its 10-year median of 4.23 and 78.5% below the Healthcare Providers & Services industry median of 2.89. Cryo-Cell International's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Cryo-Cell International (STU:ZCY), the current Net Margin % is 0.62% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (STU:ZCY) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of €3.10 is trading 49.2% below its estimated GF Value™ of €6.10.
GuruFocus considers Cryo-Cell International to be Possible Value Trap.
Key valuation signals for STU:ZCY:
Net Margin %: 0.62% (85% below median its 10-year median of 4.23)
GF Value™: €6.10 vs. price of €3.10 (49.2% below fair value)
Industry Position: 78.5% below the Healthcare Providers & Services median (#501 of 665)
No single metric tells the full story. See the STU:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score
Get the complete analysis for STU:ZCY
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ZCY has been successfully added to your 
